COMPLEXA

Complexa is a clinical-stage platform biopharmaceutical company researching and developing endogenous human cell signaling technologies targeting an array of prevalent inflammatory, fibrotic, and CNS diseases. The company's proprietary technology involves the synthesis and therapeutic applications of endogenous nitro-fatty acids (NFAs) and additional structure/function-related mediators that are designed to treat various diseases. NFAs are cell-signaling agents that regulate major inflammatory s... ignaling pathways (e.g., Nrf2, NFkB, and HSF). Capitalizing on their identification and synthesis of these endogenous signaling mediators, Complexa's technologies act to amplify the existing anti-inflammatory and metabolic signaling mechanisms that promote the resolution and repair of acute and chronic tissue injury and disease. It is headquartered in Berwyn, Pennsylvania.More